QT Interval Effects Study of Oral FXS5626 Tablets
Starting soon · Phase 1 · Has a placebo group
Conditions studied: Evaluation of QTc Interval
In brief
The purpose of this study is to evaluate the Exposure-Response Relationship Between the Plasma Drug Concentrations and the Change From Baseline in QTc interval of a single oral dose of FXS5626 in healthy subjects.
Key facts
- Study ID
- NCT07695779
- Run by
- Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
- People needed
- 28
- Starts
- 2026-08-05
- Expected to finish
- 2026-09-25
- Last updated by the study team
- 2026-07-10
Who can join
Age: 18 and older, up to 45. Sex: any. Healthy volunteers: accepted.
Where it is running
- Beijing Hospital — Beijing, Beijing Municipality, China
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.